NEW YORK – Gene therapy developer Kriya Therapeutics on Wednesday said investors have committed more than $150 million in additional Series C financing, bringing the total raised in the round to $430 million.
The funding round was led by Patient Square Capital.
Kriya, which is based in Palo Alto, California, said it will use the proceeds to advance its pipeline of gene therapies for ophthalmology, neurology, and metabolic disease and build up its engineering, computational, and manufacturing platforms.
The biopharmaceutical company is developing one-time gene therapies for common causes of blindness, such as geographic atrophy, noninfectious uveitis, and diabetic retinopathy, as well as neurological diseases like trigeminal neuralgia and epilepsy. In terms of its metabolic pipeline, the firm is working on treatments for diabetes and glycogen storage diseases.
"We look forward to the next chapter of our company's evolution as we translate our programs into the clinic where they can hopefully help patients in desperate need of better treatment options," Kriya Cofounder and CEO Shankar Ramaswamy said in a statement.
According to Kriya, it has more than $600 million in committed capital from investors since its founding in 2019. The available funds give Kriya enough cash to support operations until late 2026.